“`html
Hims & Hers Health, Inc. (HIMS) is making a strategic entry into the weight-loss market by providing affordable access to Wegovy and semaglutide treatments via telehealth. The company’s stock has seen a remarkable 150% increase over the past year, with significant growth in app downloads and web traffic, particularly following a strong Q1 2025 earnings report that doubled sales and net income year-over-year. However, the stock recently experienced a 10% decline over one week, raising concerns about the sustainability of its rapid growth.
Insider Trading Activity
In the past six months, Hims & Hers insiders executed 128 trades, all of which were sales, totaling approximately $87 million. CEO Andrew Dudum sold 1,247,836 shares for an estimated $55.4 million, while COO Melissa Baird sold 303,064 shares for about $11 million.
Recent Hedge Fund Movements
In a recent quarter, 252 institutional investors increased their HIMS shares, while 249 reduced theirs. Notably, BlackRock removed 5.9 million shares (-19.5%), and D.E. Shaw added 5.4 million shares (+841.7%).
“`
